Sonja Pettus, MD
Internal Medicine · Jasper, ALNPI 1184769424
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $108,739 of the $116,707 with a category attached, or 93.2%. CSL Behring accounts for 91.3% of it on its own, with 38 other manufacturers making up the rest. Reporting peaked in 2020 at $38,026 and has fallen 96.5% since, to $1,344 in 2025. Among internal medicine clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 573 payments — averaging $203.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$107K
- CSL Plasma Inc.$2K
- Novo Nordisk$2K
- AbbVie$1K
- Johnson & Johnson$578
- AstraZeneca$575
- plus $4K from 33 others
What the payments were for
- Consulting fees$108,73993%
- Food & beverage$7,9647%
- Education$50%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$116,707 in reported general payments places this provider in the 95th percentile of 1,533 internal medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 128 | $150,444 |
| EliquisApixaban | 116 | $86,325 |
| XareltoRivaroxaban | 84 | $75,173 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 90 | $72,447 |
| JanuviaSitagliptin Phosphate | 82 | $65,786 |
| XifaxanRifaximin | 14 | $41,436 |
| LinzessLinaclotide | 44 | $36,071 |
| JardianceEmpagliflozin | 37 | $33,096 |
| FarxigaDapagliflozin Propanediol | 44 | $32,077 |
| MounjaroTirzepatide | 17 | $30,806 |
| RexultiBrexpiprazole | 12 | $18,308 |
| EntrestoSacubitril/Valsartan | 23 | $17,368 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 16 | $16,543 |
| Breo ElliptaFluticasone/Vilanterol | 28 | $14,339 |
| TrulicityDulaglutide | 11 | $12,432 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,751 | $150,444128 claims |
| MerckJanuvia, Janumet Xr, Belsomra | $199 | $90,555118 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $494 | $86,786118 claims |
| PfizerEliquis | $307 | $86,325116 claims |
| Johnson & JohnsonXarelto | $578 | $75,17384 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $126 | $49,94126 claims |
| Lilly USA, LLCMounjaro, Trulicity | $464 | $43,23828 claims |
| AstraZenecaFarxiga, Symbicort | $575 | $39,59464 claims |
| AbbVieLinzess | $1,012 | $36,07144 claims |
| Boehringer IngelheimJardiance | $99 | $33,09637 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $94 | $18,30812 claims |
| NovartisEntresto | $254 | $17,36823 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,533 internal medicine providers in Alabama.
Other internal medicine in Jasper
- Steve JohnsonJasper$17K
- Jerry MosleyJasper$14K
- Jennifer BeasleyJasper$14K
- Ryan WeldonBirmingham$458K
- Thomas McKelveyMobile$365K
- Mary HonkanenMobile$302K
- Robert LewisBirmingham$187K
- Rosalind BowlesGadsden$168K
- Bobby WrightsMobile$89K
- Thomas HuddleBirmingham$76K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.